Research Topics
| John H StoneSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Eosinophilic angiocentric fibrosis is a form of IgG4-related systemic diseaseVikram Deshpande
Department of Pathology, Division of Rheumatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Am J Surg Pathol 35:701-6. 2011..After the serendipitous observation of an elevated serum concentration of IgG4 in 1 patient with EAF, we investigated the hypothesis that EAF is an IgG4-related systemic disease...- Vasculitis: a collection of pearls and mythsJohn H Stone
Rheumatology Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Rheum Dis Clin North Am 33:691-739, v. 2007..Over time, numerous myths and occasional pearls have arisen from the care of patients with these disorders. This collection of pearls and myths gathers lessons about the status of clinical care of vasculitis patients in the year 2008... - IgG4-related systemic disease and lymphoplasmacytic aortitisJohn H Stone
rhumatology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
Arthritis Rheum 60:3139-45. 2009..Treatment of the aortitis may prevent progression of the IgG4-related systemic disease to involvement of other organs. IgG4-related systemic disease should be considered in all patients with aortitis judged to be of unknown etiology... - Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patientsArezou Khosroshahi
Rheumatology Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Medicine (Baltimore) 91:57-66. 2012..Serum IgG4 concentrations may remain low, and clinical disease activity may remain quiescent even after B cell reconstitution in a significant proportion of patients... - Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's)Gunnar Tomasson
Boston University, Boston, Massachusetts, USA
Arthritis Care Res (Hoboken) 64:273-9. 2012..To assess a generic measure of health-related quality of life (HRQOL) as an outcome measure in granulomatosis with polyangiitis (Wegener's) (GPA)... - Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic diseaseArezou Khosroshahi
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Arthritis Rheum 62:1755-62. 2010..This study was performed to assess the clinical and serologic responses to B lymphocyte depletion therapy with rituximab in patients with IgG4-RSD... - The Clinical and Pathological Features of IgG(4)-Related DiseaseArezou Khosroshahi
Rheumatology Unit Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Curr Rheumatol Rep 13:473-81. 2011..This paper focuses on the clinical and pathological features of IgG(4)-RD... - Treatment approaches to IgG4-related systemic diseaseArezou Khosroshahi
Rheumatology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
Curr Opin Rheumatol 23:67-71. 2011..Prompt recognition and management of this disease process are necessary to prevent sclerosis and permanent organ damage. Here, we review the advances in treatment approaches to IgG4-RSD... - A clinical overview of IgG4-related systemic diseaseArezou Khosroshahi
Rheumatology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
Curr Opin Rheumatol 23:57-66. 2011..To summarize the existing knowledge of various clinical presentations of IgG4-related systemic disease (IgG4-RSD) and to review the evolving list of organs affected by IgG4-RSD... - The latest on IgG4-RD: a rapidly emerging diseaseMollie N Carruthers
Division of Rheumatology, Department of Medicine, Rheumatology Unit, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Curr Opin Rheumatol 24:60-9. 2012..Provide an update of the developments in IgG4 related disease within the last year in terms of nomenclature, diagnostic criteria and clinical features... - Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosisGunnar Tomasson
Boston University BU School of Medicine, and Massachusetts General Hospital, Boston, Massachusetts, USA
J Rheumatol 38:1048-54. 2011..Our objective was to determine whether measures of platelet activation or inflammation are associated with disease activity in Wegener's granulomatosis (WG)... - Rituximab versus cyclophosphamide for ANCA-associated vasculitisJohn H Stone
Massachusetts General Hospital, Boston, USA
N Engl J Med 363:221-32. 2010..Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen... - Subclassification of autoimmune pancreatitis: a histologic classification with clinical significanceVikram Deshpande
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, USA
Am J Surg Pathol 35:26-35. 2011..On the basis of these significant differences between the 2 types of AIP, we advocate the position that all subsequent studies attempt to substratify their patients into these 2 groups... - IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis casesJohn H Stone
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Arthritis Care Res (Hoboken) 62:316-22. 2010..We aimed to determine the percentage of noninfectious thoracic aortitis cases that are associated with IgG4-related systemic disease and to establish pathologic criteria for identifying involvement of the thoracic aorta by this disorder... - Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrumMollie Dahlgren
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Arthritis Care Res (Hoboken) 62:1312-8. 2010..quot; IgG4-related systemic disease is characterized by IgG4+ plasma cell infiltration and fibrosis throughout many organs. We hypothesized that Riedel's thyroiditis is part of the IgG4-related systemic disease spectrum... - IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myositis, and trigeminal nerve involvementZachary S Wallace
Department of Medicine, Harvard Medical School, Cambridge, Massachusetts, USA
Surv Ophthalmol 57:26-33. 2012..We review the differential of idiopathic orbital inflammatory disease, including IgG4-RD, and emphasize the need for biopsy for accurate diagnosis and to guide appropriate treatment... - Functionally defective germline variants of sialic acid acetylesterase in autoimmunityIra Surolia
Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Nature 466:243-7. 2010..9 in subjects with type I diabetes. Functionally defective SIAE rare and polymorphic variants represent a strong genetic link to susceptibility in relatively common human autoimmune disorders... - Chronic sclerosing sialadenitis (Küttner tumor) is an IgG4-associated diseaseJulia Turbiner Geyer
Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Am J Surg Pathol 34:202-10. 2010.... - Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosisAlfred D Mahr
Boston University, Boston, Massachusetts 02118, USA
Arthritis Rheum 59:884-91. 2008..To assess the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) with respect to its selection and weighting of items... - Polyarteritis nodosaJohn H Stone
Division of Rheumatology, Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
JAMA 288:1632-9. 2002..He was ultimately able to discontinue all of his immunosuppressive medications. The case is discussed in the context of the first patient ever described with PAN, the classic report of Kussmaul and Maier... - Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosisPeter K Wung
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Arthritis Rheum 59:746-53. 2008..Weight gain is a side effect of glucocorticoid (GC) use, but the natural history and health implications of changes in weight that occur during the treatment of inflammatory disease are not understood... - Small-vessel and medium-vessel vasculitisPhilip Seo
Johns Hopkins University and The Johns Hopkins Vasculitis Center, Baltimore, Maryland, USA
Arthritis Rheum 57:1552-9. 2007 - Targeted therapies in systemic vasculitisJohn H Stone
The Johns Hopkins Vasculitis Center, and Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
Cleve Clin J Med 69:SII124-8. 2002 - A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritisGary S Hoffman
Cleveland Clinic Foundation, Cleveland, Ohio 44915, USA
Arthritis Rheum 46:1309-18. 2002.... - Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trialJohn H Stone
Johns Hopkins Vasculitis Center, 5501 Hopkins Bayview Circle, JHAAC 1B 23, Baltimore, MD 21223, USA
Arthritis Rheum 48:2299-309. 2003..To report baseline data on 180 patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET), and to examine demographic and clinical differences between patients with limited disease and those with severe disease... - Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitisJohn H Stone
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Kidney Blood Press Res 26:240-8. 2003 - The antineutrophil cytoplasmic antibody-associated vasculitidesPhilip Seo
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Am J Med 117:39-50. 2004..This review describes the clinical and pathologic hallmarks of the ANCA-associated vasculitides, discusses the role of ANCA assays in diagnosis and treatment, and outlines an approach to the evaluation and management of these diseases... - Methotrexate in polymyalgia rheumatica: kernel of truth or curse of Tantalus?John H Stone
Ann Intern Med 141:568-9. 2004 - Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitisKarina A Keogh
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Arthritis Rheum 52:262-8. 2005.... - Implications of antineutrophil cytoplasmic antibody status when switching to maintenance therapyGary S Hoffman
Arthritis Rheum 53:1-2. 2005 - A serum proteomic approach to gauging the state of remission in Wegener's granulomatosisJohn H Stone
The Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
Arthritis Rheum 52:902-10. 2005..To identify serum ion patterns that distinguish remission from active disease in patients with Wegener's granulomatosis (WG)... - Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodiesOemer N Goek
The University of Heidelberg
Curr Opin Rheumatol 17:257-64. 2005.... - Classification and diagnostic criteria in systemic vasculitisAssil Saleh
The Johns Hopkins Vasculitis Center, 5501 Hopkins Bayview Circle, 1B.23, Baltimore, MD 21224, USA
Best Pract Res Clin Rheumatol 19:209-21. 2005..The Chapel Hill Consensus Conference has clarified some existing controversies in nomenclature of the systemic vasculitides. Robust diagnostic criteria for the various forms of vasculitis have, however, remained elusive... - Churg-Strauss syndrome presenting with salivary gland enlargement and respiratory distressFrancesco Boin
Vasculitis Center, The Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle 1B.23, Baltimore, MD 21224, USA
Arthritis Rheum 55:167-70. 2006 - Therapeutics of Wegener's granulomatosisPeter K Wung
Johns Hopkins Bayview Medical Center, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
Nat Clin Pract Rheumatol 2:192-200. 2006..Severe toxicity associated with the available agents and, therefore, there is keen interest in the development of alternative treatment strategies for this disease... - Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trialGary S Hoffman
Center for Vasculitis Care and Research, The Cleveland Clinic Foundation, Lerner College of Medicine, Cleveland, Ohio 44195, USA
Ann Intern Med 146:621-30. 2007..Tumor necrosis factor-alpha is present in arteries in giant cell arteritis... - Microscopic polyangiitis presenting as a "pulmonary-muscle" syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis?Julius Birnbaum
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Arthritis Rheum 56:2065-71. 2007..The histologic findings in this case implicate subclinical episodes of alveolar hemorrhage as the mechanism of interstitial lung disease in MPA... - The future of damage assessment in vasculitisPhilip Seo
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Rheumatol 34:1357-71. 2007..This initiative is part of a larger international effort to create a unified approach to disease assessment for the primary systemic vasculitides... - Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patientsStuart M Levine
Division of Rheumatology, Department of Medicine, The Johns Hopkins Vasculitis Center, Johns Hopkins University, 1830 E. Monument Street, Baltimore, MD 21205, USA
Am J Med 112:386-91. 2002..Compared with a historical cohort at our institution, mortality from this complication may have decreased, perhaps because of earlier diagnosis...